Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal

One of the most frequent oncogenic event in non-small cell lung cancer (NSCLC) is a glycine to cysteine substitution in position 12 in the V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene i.e., the KRASG12C mutation, detected in 13  % of the cases [1].

Source: Lung Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Ali Chour, Cl émence Basse, Fanny Lebossé, Pierre-Emmanuel Bonte, Nicolas Girard, Michaël Duruisseaux Source Type: research